Stem cell therapy maker Aldagen files for IPO
Stem cell drug developer Aldagen Inc. on Wednesday filed a registration for a planned initial public offering, and valued the potential IPO at $80.5 million.
[Read the full article here]Related News:
Stem cell therapy firm Aldagen withdraws plans for
Stem cell therapeutics firm Aldagen expands fundraiser to $645K
Aldagen wins FDA’s OK to test stem-cell therapy for stroke